Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Recruiting Phase 1Phase 2 Interventional

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT07596901
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Aritinercept, Placebo
Drug · Other
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Pasadena, California • Altamonte Springs, Florida • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Topiramate to Aid Smoking Cessation in Alcohol Dependent Men

NCT00802412
View directory record Official record
Conditions
Nicotine Dependence, Alcohol Dependence
Interventions
Topiramate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

NCT03983681
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 59 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
East Hanover, New Jersey • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Effects of Vigabatrin on Cocaine Self-Administration

NCT00373581
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Vigabatrin, Cocaine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline and Combined NRT for Smoking Cessation

NCT02271919
View directory record Official record
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Nicotine Lozenge, Nicotine Patch, Placebo, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

NCT01755767
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tivantinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

NCT02177136
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
33
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 3 Interventional Results available

NAC for Head Trauma-induced Anosmia

NCT03680911
View directory record Official record
Conditions
Anosmia, Head Trauma
Interventions
N Acetyl Cysteine, Placebo oral capsule
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Hydroxychloroquine In Covid-19 Kinetics

NCT04353271
View directory record Official record
Conditions
Covid 19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 24, 2026, 2:14 PM EDT
Withdrawn Not applicable Interventional

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 24, 2026, 2:14 PM EDT
Suspended Phase 2Phase 3 Interventional

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

NCT05107934
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Vitamin D Administration in the Nursing Home

NCT00204919
View directory record Official record
Conditions
Vitamin D Deficiency, Osteoporosis
Interventions
Vitamin D, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Not applicable Interventional

Treatment of Rhinitis With Intranasal Vitamin E

NCT00281307
View directory record Official record
Conditions
Rhinitis
Interventions
RRR-alpha-tocopherol 1,000 IU/mL
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT05614544
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, Propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Not listed Phase 2 Interventional

Pulmozyme to Improve COVID-19 ARDS Outcomes

NCT04402944
View directory record Official record
Conditions
COVID
Interventions
Pulmozyme, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 2:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular Function

NCT01968564
View directory record Official record
Conditions
Vascular Aging
Interventions
Placebo pill, High-dose curcumin pill, Low-dose curcumin pill
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition for Brain and Body Health (BB-Health) Feasibility Trial

NCT05542199
View directory record Official record
Conditions
Cognition, Obesity
Interventions
Multicomponent nutrition supplement (MCNS), Behavioral weight loss program
Other · Behavioral
Lead sponsor
Tufts University
Other
Eligibility
55 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

NCT00345332
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Botox, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Sacramento, California • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 24, 2026, 2:14 PM EDT